Drugs / IBCASERTIB
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05346601 | Jun 2022 | — | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03216343 | Nov 2017 → Nov 2022 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03074825 | May → Aug 2017 | non-Hodgkin lymphoma | Chipscreen Biosciences, Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT02122809 | Feb 2014 → Apr 2016 | cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05271292 | Aug 2022 → Mar 2025 overdue | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05505825 | Aug 2022 → Jul 2024 | small cell lung carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT03974243 | Jul 2019 → Dec 2021 | non-Hodgkin lymphoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03245190 | Apr 2018 → Nov 2019 | hepatocellular carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03166891 | Dec 2017 → Mar 2019 | ovarian cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06492915 | Aug 2024 → May 2026 overdue | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05497843 | Aug 2022 → Jan 2025 | soft tissue sarcoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05336721 | Nov 2021 → Oct 2024 | triple-negative breast carcinoma | Chipscreen Biosciences, Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03901118 | Jul 2019 → Dec 2020 | ovarian cancer | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07445295 | Mar 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04921527 | Dec 2021 → Dec 2024 overdue | ovarian cancer | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04830813 | Mar 2021 → Apr 2024 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05371899 | Jul 2022 → Mar 2024 | small cell lung carcinoma | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-16 | Chipscreen Biosciences, Ltd. | Regulatory Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA) chipscreen.com ↗
With this clearance of US FDA IND application for CS2164, it will certainly increase success of our global development strategy based on early efficacy and safety data obtained from China trials. |
| 2021-01-11 | Chipscreen Biosciences, Ltd. | Regulatory Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N chipscreen.com ↗
The submission has been accepted by the Center of Drug Evaluation of the NMPA. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-16 | Chipscreen Biosciences, Ltd. | Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA) chipscreen.com ↗ |
| 2021-01-11 | Chipscreen Biosciences, Ltd. | Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N chipscreen.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBCASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095033 ↗ |
| Known as | Chiauranib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03166891 ↗ |
| Known as | CS-2164 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095033 ↗ |
| Action | Inhibit | “Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit),...” PMID 30642372 ↗ Jan 20191“Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL5095033 ↗ |
| Modality | Small molecule | “Chiauranib is a novel small-molecule selective inhibitor” PMID 39123210 ↗ Aug 2024 |
| Route | Oral | “Take orally” NCT02122809 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL5095033 ↗ |